Trillium Therapeutics Reports Second Quarter 2018 Financial and Operating Results
Trillium Therapeutics Inc. - Common Shares (TRIL)
Last trillium therapeutics inc. - common shares earnings: 5/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
trilliumtherapeutics.com/investors/news/default.aspx
Company Research
Source: GlobeNewswire
Increased focus on T cell lymphoma in lead program, TTI-621 Initiated dosing of TTI-622 (SIRPaFc IgG4) in phase 1a/1b clinical trial Recruited Dr. Yaping Shou as Chief Medical OfficerNegotiated improved SIRPaFc license agreement TORONTO, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial and operating results for the six months ended June 30, 2018. “We are continuing to build upon the observed single-agent activity of TTI-621, our lead CD47 blocking agent, in T cell lymphoma patients, and are also now dosing patients with TTI-622, our second SIRPaFc decoy receptor,” said Dr. Niclas Stiernholm, president and CEO of Trillium Therapeutics. “With two unique CD47-directed therapies in clinical testing, and strong support and enthusiasm from our clinical collaborators, we continue our role as a leader in the field of CD47 research.
Show less
Read more
Impact Snapshot
Event Time:
TRIL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TRIL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TRIL alerts
High impacting Trillium Therapeutics Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics